HER2-Positive Early Breast Cancer: Interpreting DESTINY-Breast11 Trial Design

Dr. Neil Iyengar moderates a discussion with Dr. Alison Conlin and Dr. Kelly McCann on the design of the DESTINY-Breast11 trial and its implications for the management of HER2-positive early breast cancer. The faculty examine the use of an anthracycline-containing control arm, noting its continued relevance for high-risk patients in many regions while acknowledging that practice patterns in the United States have increasingly shifted toward anthracycline-sparing approaches. Dr. Conlin discusses the high-risk characteristics of the enrolled patient population and explains why the selected comparator remains clinically meaningful, whereas Dr. McCann considers how evolving treatment strategies and prior studies have influenced current practice. The discussion highlights the importance of understanding trial design and control arm selection when interpreting emerging clinical data and explores how these considerations may affect the translation of DESTINY-Breast11 findings into routine management of patients with high-risk HER2-positive early breast cancer.